ArrowMark Colorado Holdings LLC Acquires 105,600 Shares of Kenvue Inc. $KVUE

ArrowMark Colorado Holdings LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 132.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 185,557 shares of the company’s stock after buying an additional 105,600 shares during the period. ArrowMark Colorado Holdings LLC’s holdings in Kenvue were worth $3,012,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in KVUE. Vanguard Group Inc. increased its position in shares of Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after acquiring an additional 4,101,880 shares in the last quarter. American Century Companies Inc. lifted its position in Kenvue by 22.4% in the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after acquiring an additional 6,781,640 shares in the last quarter. Independent Franchise Partners LLP boosted its stake in Kenvue by 233.4% during the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. Norges Bank acquired a new position in Kenvue during the 2nd quarter valued at about $537,418,000. Finally, Dimensional Fund Advisors LP increased its holdings in Kenvue by 13.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock worth $375,377,000 after purchasing an additional 2,747,952 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $17.51 on Monday. The company has a market capitalization of $33.55 billion, a PE ratio of 22.73, a PEG ratio of 3.97 and a beta of 0.51. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $17.89 and its 200-day moving average price is $17.27. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.During the same period last year, the business posted $0.26 earnings per share. Kenvue’s revenue was up 3.2% on a year-over-year basis. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 107.79%.

Analysts Set New Price Targets

Several brokerages have recently commented on KVUE. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Citigroup increased their price target on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Finally, UBS Group lifted their price objective on shares of Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.